Sign in

Christopher Boyer

@cboyer.bsky.social
225 followers 378 following 83 posts

Assistant Professor, Case Western Reserve University (CCLCM). Staff Biostatistician, Cleveland Clinic. Epidemiologist interested in causal inference, infectious disease, trial design christopherbboyer.com/about.html #causalsky #statssky #episky

PostsRepliesMedia
Reposted by Christopher Boyer
Darren Dahly @statsepi.bsky.social · 11/02/2026
A PhD candidate at Harvard Nutrition steps forward, head bowed. Walter Willett, dressed in full regalia, solemnly reaches into two fishbowls. One is full of slips of paper with nutrients/foods on them. The other, diseases. The random pair he withdraws is their dissertation topic. *Trumpets sound*
84911
Christopher Boyer @cboyer.bsky.social · 17/01/2026
What I want: a handful of rigorous, randomized evaluations of AI use in science with clear protocols of use, careful measurement, and real endpoints. What I am getting: a million sloppy studies either using AI to crawl massive publication databases or little trials reporting nonserious benchmarks.
030
Reposted by Christopher Boyer
Lorenzo Fabbri @epilorenzo.bsky.social · 16/01/2026
Very interesting! I became quite obsessed with negative controls/test lately 😅 I’m trying to put several methods in here: github.com/etverse/negatr
github.com
GitHub - etverse/negatr: R package for negative control analysis.
R package for negative control analysis. Contribute to etverse/negatr development by creating an account on GitHub.
121
Christopher Boyer @cboyer.bsky.social · 16/01/2026
New blog post: christopherbboyer.com/posts/2025-1... A simple simulation to show when/how test-negative results can be used to correct unmeasured confounding.
christopherbboyer.com
Can test-negative results correct hidden confounding? – Christopher B. Boyer
A simulation walk-through of negative control outcomes for vaccine effectiveness
221
Christopher Boyer @cboyer.bsky.social · 30/12/2025
Glad this is receiving more scrutiny. Our own fertility journey included not only encounters with private equity owned clinics but also black market deals for drugs due to manufactured shortages. Shares many of the predatory tactics of other industries that prey on vulnerable people.
110
Reposted by Christopher Boyer
Saloni @scientificdiscovery.dev · 09/12/2025
Big new blogpost! My guide to data visualization, which includes a very long table of contents, tons of charts, and more. --> Why data visualization matters and how to make charts more effective, clear, transparent, and sometimes, beautiful. www.scientificdiscovery.dev/p/salonis-gu...
screenshot of my post
28806313
Christopher Boyer @cboyer.bsky.social · 10/12/2025
Today I had to docu-sign some legal agreements for grants and noticed they now offer an AI summary that they warn “may be inaccurate”… Truly what are we doing here fam?
030
Reposted by Christopher Boyer
Julia M. Rohrer @dingdingpeng.the100.ci · 09/12/2025
I maintain that this is an excellent benchmark for d-type effect sizes: Sleep satisfaction & duration declined with childbirth & reached a nadir during the first 3 months postpartum, with women more strongly affected (satisfaction d = -0.79, duration minus 62 min, d = -0.90)>
academic.oup.com
Long-term effects of pregnancy and childbirth on sleep satisfaction and duration of first-time and experienced mothers and fathers
AbstractStudy Objectives. To examine the changes in mothers’ and fathers’ sleep satisfaction and sleep duration across prepregnancy, pregnancy, and the pos
68125
Christopher Boyer @cboyer.bsky.social · 02/12/2025
Now published! journals.lww.com/epidem/abstr...
journals.lww.com
060
Reposted by Christopher Boyer
Pausal Zivference @pausalz.bsky.social · 28/10/2025
If you've ever found any of my work helpful, consider donating to the Python Software Foundation Learning Python during my PhD and translating everything between programming languages helped me build my understanding of causal inference. It is also why I know estimating equations as well as I do
0103
Reposted by Christopher Boyer
JAMA @jama.com · 16/10/2025
Among preterm infants with severe thrombocytopenia, this modeling study found substantial variation among individuals in predicted benefits and harms of prophylactic platelet transfusion based on their current clinical characteristics. ja.ma/43esYCF
Figure 3: Risk estimates by transfusion strategy. A scatter plot compares observed vs. predicted risk of bleeding/death, with prophylaxis & no prophylaxis groups. Prophylaxis has lower discrimination. Histograms show risk distribution.
033
Reposted by Christopher Boyer
Emily Moin @emilymoin.com · 10/10/2025
I am open to the idea that there are people who don't have and don't want to gain the skills to engage directly with their data but every single day that I do I learn the answer to a question you'd never even think to ask unless you were personally staring into the abyss of an uncleaned dataset.
58011
Reposted by Christopher Boyer
Pausal Zivference @pausalz.bsky.social · 09/10/2025
For years I had trouble following some of the discussion about confidence bands, but at ACIC this year @noahgreifer.bsky.social pointed me to a helpful paper So you don't have to be as perplexed as I once was, we have a new pre-print introducing the key ideas arxiv.org/abs/2510.07076
arxiv.org
Confidence Regions for Multiple Outcomes, Effect Modifiers, and Other Multiple Comparisons
In epidemiology, some have argued that multiple comparison corrections are not necessary as there is rarely interest in the universal null hypothesis. From a parameter estimation perspective, epidemio...
1208
Reposted by Christopher Boyer
Pausal Zivference @pausalz.bsky.social · 09/10/2025
I have an interesting case study on this actually. So at the beginning of the semester, I was preparing a bit on the (mis)use of LLMs for the course I co-teach One of things I did was have it summarize one of my own papers, since people say "it's so good at it" arxiv.org/abs/2503.02789
arxiv.org
Accounting for Missing Data in Public Health Research Using a Synthesis of Statistical and Mathematical Models
Introduction: Missing data is a challenge to medical research. Accounting for missing data by imputing or weighting conditional on covariates relies on the variable with missingness being observed at ...
252
Christopher Boyer @cboyer.bsky.social · 08/10/2025
In another paper out this week, we also discuss an alternative approach --- i.e., transporting prediction models derived in a trial setting to a target population. 👉 doi.org/10.1186/s415...
doi.org
Counterfactual prediction from machine learning models: transportability and joint analysis for model development and evaluation using multi-source data - Diagnostic and Prognostic Research
Background When a machine learning model is developed and evaluated in a setting where the treatment assignment process differs from the setting of intended model deployment, failure to account for this difference can lead to suboptimal model development and biased estimates of model performance. Methods We consider the setting where data from a randomized trial and an observational study emulating the trial are available for machine learning model development and evaluation. We provide two approaches for estimating the model and assessing model performance under a hypothetical treatment strategy in the target population underlying the observational study. The first approach uses counterfactual predictions from the observational study only and relies on the assumption of conditional exchangeability between treated and untreated individuals (no unmeasured confounding). The second approach leverages the exchangeability between treatment groups in the trial (supported by study design) to “transport” estimates from the trial to the population underlying the observational study, relying on an additional assumption of conditional exchangeability between the populations underlying the observational study and the randomized trial. Results We examine the assumptions underlying both approaches for fitting the model and estimating performance in the target population and provide estimators for both objectives. We then develop a joint estimation strategy that combines data from the trial and the observational study, and discuss benchmarking of the trial and observational results. Conclusions Both the observational and transportability analyses can be used to fit a model and estimate performance under a counterfactual treatment strategy in the population underlying the observational data, but they rely on different assumptions. In either case, the assumptions are untestable, and deciding which method is more appropriate requires careful contextual consideration. If all assumptions hold, then combining the data from the observational study and the randomized trial can be used for more efficient estimation.
010
Christopher Boyer @cboyer.bsky.social · 08/10/2025
🚨 New paper in Statistics in Medicine! We develop a framework for estimation and evaluation of prediction models that aim to answer causal questions — i.e., what would happen under hypothetical interventions. 👉 onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
Estimating and Evaluating Counterfactual Prediction Models
Counterfactual prediction methods are required when a model will be deployed in a setting where treatment policies differ from the setting where the model was developed, or when a model provides pred....
141
Christopher Boyer @cboyer.bsky.social · 02/10/2025
#statsky If I’m writing a protocol for 1) developing a prediction model and 2) an RCT to test implementation of said model within a health system would you publish 1 and 2 together or separately or neither?
111
Reposted by Christopher Boyer
Marc Lipsitch @mlipsitch.bsky.social · 22/05/2025
Time Sensitive: Public comment on Schedule F (removing civil service protections for many federal employees INCLUDING THOSE WITH AUTHORITY OVER GRANTS) ends tomorrow. Notice is here: www.govinfo.gov/content/pkg/... . Comment here (green button) www.federalregister.gov/documents/20... .
govinfo.gov
12419
Christopher Boyer @cboyer.bsky.social · 12/05/2025
You have a trial with following characteristics: participants are recruited and randomly assigned 1:1 to an intervention delivered in groups or control. Those assigned to intervention are further randomized to the group they are to receive intervention in. QUESTION: is this a “cluster” RCT? #stats
231
Reposted by Christopher Boyer
Christopher Boyer @cboyer.bsky.social · 05/05/2025
New preprint with Kendrick Li, Xu Shi, and Eric Tchetgen Tchetgen! We revisit the test-negative design (TND) and propose alternative identifiability assumptions and estimators of vaccine effectiveness (VE) under “equip-confounding". arxiv.org/abs/2504.20360
arxiv.org
Identification and estimation of vaccine effectiveness in the test-negative design under equi-confounding
The test-negative design (TND) is frequently used to evaluate vaccine effectiveness in real-world settings. In a TND study, individuals with similar symptoms who seek care are tested for the disease o...
041
Christopher Boyer @cboyer.bsky.social · 05/05/2025
New preprint with Kendrick Li, Xu Shi, and Eric Tchetgen Tchetgen! We revisit the test-negative design (TND) and propose alternative identifiability assumptions and estimators of vaccine effectiveness (VE) under “equip-confounding". arxiv.org/abs/2504.20360
arxiv.org
Identification and estimation of vaccine effectiveness in the test-negative design under equi-confounding
The test-negative design (TND) is frequently used to evaluate vaccine effectiveness in real-world settings. In a TND study, individuals with similar symptoms who seek care are tested for the disease o...
041
Reposted by Christopher Boyer
Darren Dahly @statsepi.bsky.social · 24/04/2025
These people are dangerous, and I mean that. academic.oup.com/pnasnexus/ad...
In silico trials and digital twins are emerging as transformative medical technologies as they offer a unique way to design medical innovations, optimize their application, and evaluate their utility. Their utility spans from individual care – appropriating the technology for personalized decision, to population care – presenting an alternative to design, supplement, or replace clinical trials. They effectually offer a new way to efficiently qualify, quantify, and personalize healthcare innovations in advance or in conjunction with their clinical application. While much progress is underway to advance these technologies across diverse developments, realizing their full potential requires a cohesive goal to unify separate activities towards a common objective. Such a cohesive goal – a moonshot – can be defined as forming and fostering a digital twin of every single human person, owned by the individual, progressively updated with new data, and used to deliver optimized care, technology assessment, and real-world evidence. This vision builds upon a growing body of work in computational modeling, regulatory science, and digital healthcare, underscoring its feasibility. Bringing this vision to reality requires ownership and active engagement of all stakeholders to contribute diverse expertise and resources for transforming medicine and medical appropriation towards a more accurate, efficient, and quantitative future.
97417
Reposted by Christopher Boyer
Christopher Boyer @cboyer.bsky.social · 24/02/2025
Thesis: most published findings are false/waste and we need a movement to fix this. Antithesis: science reform is broken, falls prey to same tendency to overclaim, and is politically weaponized. Synthesis: ????
331
Reposted by Christopher Boyer
Jon Huang @jonhuang.bsky.social · 24/02/2025
I have confirmation from my (HI) State DOH that PRAMS is paused as of last Thurs. All new data collected after Jan 31 are rejected. Which epis in other states, esp those without large MCH research presence, are interested in standing up alternatives? Also an opportunity to educate on data! 📩 me!
12916
Reposted by Christopher Boyer
lastpositivist.bsky.social @lastpositivist.bsky.social · 24/02/2025
I agree that there's a lot of bad science out there and am, er, somewhat sceptical of the quality control mechanisms we have to put the point mildly. But, like, point estimates of the amount of research waste are, to me, just on their face very implausible. I don't think I could possibly trust that?
169113
Reposted by Christopher Boyer
Noah Haber @whaleactually.com · 24/02/2025
Yeah it's a mess out there (here?) But there is a reason I am working in the science reform movement (such as it is): There are actual potential paths forward that build on what the science reform movement has made over the last decade. But no easy solutions.
011
Christopher Boyer @cboyer.bsky.social · 24/02/2025
Thesis: most published findings are false/waste and we need a movement to fix this. Antithesis: science reform is broken, falls prey to same tendency to overclaim, and is politically weaponized. Synthesis: ????
331
Christopher Boyer @cboyer.bsky.social · 05/02/2025
I feel like there hasn’t been enough reporting on the fact that there’s effectively a 21st century patronage system now in which far more people are bound financially to the “success” of the dear leader than any 19th century political boss could have dreamed.
000
Reposted by Christopher Boyer
Erin A. Snider @erinsnider.bsky.social · 01/02/2025
Very concerning news about the future of USAID from Sen Murphy below:
13493148
Reposted by Christopher Boyer
Edward H. Kennedy @edwardhkennedy.bsky.social · 13/01/2025
"Randomized trials should be used to answer any causal question that can be so studied... But the reality is that observational methods are used everyday to answer pressing causal questions that cannot be studied in randomized trials." - Jamie Robins, 2002 tinyurl.com/4yuxfxes tinyurl.com/zncp39mr
2253
Reposted by Christopher Boyer
Yonatan Grad @yhgrad.bsky.social · 15/12/2024
Now published in AJE: academic.oup.com/aje/advance-...
academic.oup.com
Estimating the undetected burden and the likelihood of strain persistence of drug-resistant Neisseria gonorrhoeae
Abstract. Neisseria gonorrhoeae has developed resistance to all antibiotics recommended for treatment and reports of reduced susceptibility to ceftriaxone,
0173
Christopher Boyer @cboyer.bsky.social · 14/12/2024
Does anyone know any literature on randomization-based inference for sequential trials? As you add time points I assume the randomization distribution quickly gets quite complex and wonder if there are more efficient sampling strategies?
000
Reposted by Christopher Boyer
Marc Lipsitch @mlipsitch.bsky.social · 24/11/2024
New preprint out with Ziyuan Zhang (master's student) and Chris Boyer www.medrxiv.org/content/10.1... showing through simulation that a variant of the test-negative design can estimate the protection associated with an exposure-proximal correlate of protection for immunity to symptomatic infection
medrxiv.org
Use of the test-negative design to estimate the protective effect of a scalar immune measure: A simulation analysis
Background: The relationship between antibody levels (more generally, a scalar measure of immune protection) at the time of exposure to infection (so-called exposure-proximal correlates of protection)...
0122
Christopher Boyer @cboyer.bsky.social · 29/10/2024
How much of academia is just reformatting your CV to another new template?
000
Christopher Boyer @cboyer.bsky.social · 30/05/2024
Decided today my safe word is “mimics randomization”.
000
Reposted by Christopher Boyer
Maarten van Smeden @maartenvsmeden.bsky.social · 04/12/2023
NEW PREPRINT Using the estimands framework for prediction models with updated predictions over time arxiv.org/abs/2311.17547
0128
Christopher Boyer @cboyer.bsky.social · 22/11/2023
A lot of (understandable) concern about ChatGPT flooding science with fake papers and fake data, but it’s at least mildly amusing that so far it’s mostly humans flooding the zone with mediocre papers about ChatGPT.
120
Christopher Boyer @cboyer.bsky.social · 27/09/2023
New pre-print with Issa Dahabreh and Jon Steingrimsson on assessing the performance of counterfactual prediction models. arxiv.org/abs/2308.13026
arxiv.org
062
Christopher Boyer @cboyer.bsky.social · 27/09/2023
New pre-print with marc lipsitch on target trial design and emulation for postexposure vaccination. Estimating VE for PEV is challenging due to overlap between disease onset and vaccine timing. We discuss possible designs and estimands as well as how to emulate them. www.medrxiv.org/content/10.1...
medrxiv.org
Defining and emulating target trials of the effects of postexposure vaccination using observational ...
medRxiv - The Preprint Server for Health Sciences
051